問卷

TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of Neurology

更新時間:2023-09-19

王文甫
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

18Cases

2026-08-01 - 2035-12-31

Phase III

Not yet recruiting
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
  • Condition/Disease

    Alzheimer's Disease

  • Test Drug

    注射液劑

Participate Sites
8Sites

Not yet recruiting1Sites

2026-09-01 - 2028-12-31

Phase II

Not yet recruiting
An Exploratory Phase 2 Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Investigate the Safety, Tolerability, and Efficacy of TML-6 in Early Alzheimer's Disease
  • Condition/Disease

    Alzheimer Disease

  • Test Drug

    錠劑

Participate Sites
9Sites

Not yet recruiting9Sites

2018-06-01 - 2023-03-21

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated6Sites

2021-02-01 - 2027-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2013-02-01 - 2017-05-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2009-12-01 - 2014-01-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2025-01-01 - 2031-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2014-02-01 - 2016-01-31

Phase III

Acute Stroke Or Transient IsChemic Attack TReated with Aspirin or Ticagrelor and Patient OutcomES
  • Condition/Disease

    Patients with an acute cerebral ischemic event (minor stroke/high-risk TIA) and high risk of subsequent ischemic stroke, who could be randomised within 24 hours of symptom onset

  • Test Drug

    Ticagrelor

Participate Sites
11Sites

Terminated10Sites

Study ended1Sites

2007-06-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

1 2